本年度信息
2026年2月26日，康希诺生物股份公司披露2025年度主要财务数据。报告期内，公司实现营业总收入约人民币1,067.91百万元，同比增长26.18%。经调整净亏损（扣除非经常性损益后）约为人民币92.50百万元，较上一年度的亏损441.25百万元显著收窄。
公告显示，公司继续推进以创新为核心、以商业化落地为重点的发展策略，旗下四价流脑结合疫苗曼海欣®保持增长。同时，通过成本控制和资源配置优化，公司在期间多项费用得到有效管控，盈利能力提升。公司还获得政府专项补助和国际专项研发资金支持，并将相应收益计入业绩。
业务分项
报告期内，四价流脑结合疫苗曼海欣®纳入相关医疗保障后继续带动收入增长，公司在降本增效和产销协同上均有所突破，进一步提升了毛利率。与此同时，国际合作项目的推进也为其研发投入带来更多经营协同。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.